Gilead Sciences | GILD - Ebitda

Stock Price
146.26
Daily Change
2.98 2.08%
Monthly
23.63%
Yearly
46.77%
Q1 Forecast
137.58

Gilead Sciences reported $4.03B in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Agios Pharmaceuticals USD -125.8M 20.45M Jun/2025
ALKERMES USD 121.55M 4.99M Sep/2025
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
Amgen USD 5.91B 2.31B Sep/2025
Biogen USD 1.01B 456.5M Jun/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Incyte USD 581.52M 358.87M Jun/2025
J&J USD 9.52B 389M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Moderna USD -208M 552M Sep/2025
Neurocrine Biosciences USD 246.7M 93.8M Sep/2025
Novartis USD 5.88B 290M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
PTC Therapeutics USD -33.11M 1B Jun/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Sanofi EUR 4.84B 2.95B Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
United Therapeutics USD 436.8M 34.2M Jun/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025